Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Alterity Therapeutics Ltd. ( (AU:ATH) ) has issued an update.
Alterity Therapeutics Limited has requested a trading halt on its securities pending the release of results from its Phase II clinical trial. This halt, effective immediately, is anticipated to last until the announcement of the trial results or the commencement of trading on January 30, 2025. The trading halt suggests the importance of the upcoming trial results, potentially impacting Alterity’s market position and stakeholder interests.
More about Alterity Therapeutics Ltd.
Alterity Therapeutics Limited operates in the biotechnology industry, specializing in developing therapies for neurodegenerative diseases. The company is focused on advancing treatments that address disorders such as Parkinson’s disease and Alzheimer’s, with a particular emphasis on innovative approaches through clinical trials.
YTD Price Performance: 0%
Average Trading Volume: 100
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $26.76M
For an in-depth examination of ATH stock, go to TipRanks’ Stock Analysis page.
